Replimune, Inc.

This early-stage study tests a new drug called RP3, alone or with an immunotherapy, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is not a cure, but aims to control the diseas…

This study tests a new treatment called RP1, a virus that attacks cancer cells, combined with the immunotherapy drug nivolumab. It includes 340 adults with advanced solid tumors such as melanoma, non-small cell lung cancer, and certain skin cancers. The goal is to see if the comb…

This study tests a drug called RP1, which is injected directly into skin cancer tumors. It is for people who have had an organ or stem cell transplant and now have advanced skin cancer. The goal is to see if RP1 can shrink tumors safely without harming the transplanted organ. Abo…

This program provides early access to an experimental treatment for adults with advanced melanoma that has worsened after standard anti-PD-1 therapy. Participants receive a combination of vusolimogene oderparepvec (VO) and nivolumab. The goal is to offer potential benefit to elig…

This early-stage study tests a new drug, RP2, in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if RP2 works better when combined with another immunotherapy. The study focuses on safety and tumor re…